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Subclinical hypothyroidism (sHT) is a common condition in the general population, the
prevalence increases with age, especially in women. An association between sHT and
increased coronary heart disease (CHD) and heart failure (HF) risk and mortality has been
described. However, this association is far to be established in older people (>65 years),
especially in the oldest old (>85 years). Individuals with sHT may experience symptoms
that resemble those observed in the overt form of the disease, leading to an impaired
quality of life (QoL). Although very old people are frequently frail and potentially more sus-
ceptible to the effects of a disease, few studies were designed to assess the effect of
sHT on QoL in this subset of population. Interestingly, the serumTSH concentration curve
of general population has a skewed distribution with a “tail” toward higher values, which
is amplified with aging. Thus, the diagnosis of sHT and the interpretation of its potential
effects on CV function and QoL in older people may be a challenge for the clinician. Giving
these premises, we reviewed the English scientific literature available on National Library
of Medicine (www.pubmed.com) since 1980 regarding hypothyroidism, sHT, elderly, car-
diovascular risk, CHD or HF events and mortality, health-related QoL, and LT4 therapy.
Consistent results among large prospective cohort studies suggest an age-independent
relationship between sHT and HF progression, while an impact of sHT on CHD events
and mortality is essentially reported in young adults (aged below 65–70 years) with long-
lasting disease. Scanty data are available on QoL of older people with sHT (>65 years) and,
generally, no significant alterations are described.
Keywords: elderly, subclinical hypothyroidism,quality of life, cardiovascular risk, cardiovascular events,heart failure,
ischemic heart disease, mortality
INTRODUCTION
Subclinical hypothyroidism (sHT), defined as serum TSH con-
centration above the upper limit of the reference range in the
face of normal free T4 (FT4) and free T3 (FT3) levels, is a com-
mon condition in older people, especially among women (1–3).
This biochemical condition encompasses several pathological enti-
ties, mainly represented by chronic autoimmune thyroiditis. sHT
is often associated to symptoms that resemble those of overt
hypothyroidism, although to a lesser extent thus, the expression
“mild thyroid impairment” or “mild thyroid hormone deficiency”
would be more appropriate for defining such a condition (1).
Nonetheless, the term sHT is recognized worldwide and will be
utilized in the present review, too. In the last decades, an associa-
tion between sHT and increased cardiovascular (CV) risk has been
described, although depending on the degree of TSH elevation (1,
4, 5). However, this relationship in older individuals is far to be
established (6–9). Although very old people are frequently frail and
potentially more susceptible to the effects of a disease, few studies
were designed to assess the effect of sHT on quality of life (QoL) in
this subset of population. Moreover, the serum TSH concentration
curve of general population has a skewed distribution with a “tail”
toward higher values, which is amplified with aging (6, 7). Thus,
the diagnosis of sHT and the interpretation of its potential effects
on CV function and QoL in older people may be a challenge for the
clinician. Thus, better understanding of these topics could, at least
partially, resolve the question of whether treating older people,
especially the oldest old (aged> 85 years), with sHT is appropri-
ate, especially in case of slight elevation (from >4 to <10 mIU/l)
of serum TSH value. Given these premises, we reviewed the Eng-
lish scientific literature available on National Library of Medicine
(www.pubmed.com) since 1980 regarding hypothyroidism, sHT,
elderly, CV risk, coronary heart disease (CHD) or heart failure
(HF) events and mortality, health-related QoL, and LT4 therapy.
THYROID FUNCTION AND AGING
The relationship between thyroid function and aging has been
hypothesized more than almost two decades ago (8). Several clini-
cal studies confirmed an age-dependent decrease of thyroid func-
tion including iodine uptake and thyroid hormone production (9).
However, it should be underlined that direct age-related changes
need to be distinguished from the actual alterations induced by
thyroid diseases or non-thyroidal illness. In this setting, conflict-
ing results still exist regarding the serum TSH reference range and
its modification with aging between earlier reports (mainly case-
control or cross-sectional) and recent large naturalistic studies (3,
7, 8, 10–14). Given that sHT is essentially recognized as abnormal
serum TSH elevation, the definition of a worldwide recognized
age-related reference range is clearly warranted.
www.frontiersin.org October 2014 | Volume 5 | Article 153 | 1
Tognini et al. Sublinical hypothyroidism in older people
In the study by Mariotti et al. (8), healthy centenarians showed
a relatively low prevalence of sHT (7%) in the face of reduced
serum FT3 levels as compared to either young adults or older
people (>65 years). Interestingly, a progressive decrease of serum
TSH levels from young adults up to older people and centenar-
ians was observed. The study raised the question whether the
decreased FT3 and TSH values represented an adaptive mechanism
to reduced metabolic homeostasis or a protective condition in
aging. Moreover, the age-related changes of thyroid status should
be distinguished from the “no-thyroidal illness syndrome” (fre-
quently observed in older people), in which serum FT3 decreases
while FT4 (within the normal range of healthy adults) and reverse
T3 (above the normal range of healthy adults) increase. Indeed, the
low serum T3 of non-thyroidal illness syndrome reflects a catabolic
state and is associated with a lower physical function and poorer
prognosis (15, 16). At partial odds with the earlier reports (8, 14),
more recent population-based and cross-sectional studies (6, 7)
showed a progressive shift of the normal serum TSH range toward
higher values from healthy young individuals up to centenarians. A
possible interpretation of this finding could be the presence of low
bioactive isoforms of circulating TSH (17). Since TSH bioactivity
is related to post-translational modifications such as sialylation,
sulfation, and glycosylation that could be affected by the aging
process, TSH immunoreactivity cannot be assumed to represent
TSH bioactivity at all. Thus, it is possible that differences in TSH
bioactivity as well as alterations of renal or liver function could
account for some of the discrepancies of literature in older people.
Unfortunately, current assays for serum TSH measurement cannot
distinguish different TSH isoforms and we can only speculate on
this finding without certain evidences.
Overall, however, available data suggest that aging is associated
with a certain degree of down-regulation of the hypothalamus
pituitary–thyroid-peripheral axis, although the clinical signifi-
cance of such condition and the effectiveness of LT4 replacement
therapy are far to be established, especially in the elderly (9, 18).
Indeed, thyroid hormones (TH) are implicated in maintaining
and integrating metabolic homeostasis at multiple levels, notably
not only in the hypothalamus but also in peripheral tissues. In
detail, TH may affect cell membrane composition, inflamma-
tory response, and stem cell renewal. Interestingly, data from
both human beings and animal models showed a negative cor-
relation between serum TH value and longevity. Bowers et al.
(19) recently reviewed the available literature on the putative
TH-related mechanisms that could be implicated in modulating
lifespan of mammals, including human beings. They argued that
constraints on TH signaling at certain life stages, notably during
old age, could be advantageous for optimal aging. Accordingly,
Rozing et al. reported that the offspring of nonagenarian siblings
presented a lower thyroidal sensitivity to TSH and a paradoxical
beneficial cardio-metabolic profile as compared to their partners
(20). Moreover, better survival and performance status has been
described in very old people (>85 years) with mild thyroid failure
(10, 21–23).
As a whole, these findings suggest that a certain degree of down-
regulation of thyroid function may exert a beneficial effect during
aging and might represent a protective factor in the oldest old
population. It should be underlined, however, that most data were
obtained in animal models, mainly rodents, and a parallel with
human beings should be cautiously interpreted.
EPIDEMIOLOGY OF sHT
Human aging, especially in women, is associated with increased
prevalence of circulating anti-thyroid antibodies and mild to full-
blown thyroid failure (2, 3, 10, 18, 24, 25). In this setting, however,
the sensitivity of the TSH assay utilized in the study and the
cut-off value used for defining sHT, which ranged from >3.0 to
>7.0 mIU/l (26, 27) should be taken into account. Moreover, giv-
ing the high prevalence of anti-thyroid antibodies observed in
individuals with circulating TSH value above 2.5 mIU/l, such cut-
off has been also proposed for defining sHT (28, 29). Thus, it is not
surprising that the reported prevalence of sHT ranges widely from
1.3 to 21% (24–27, 30–32). Besides the different cut-off values,
another factor responsible for the wide variability of sHT preva-
lence is the heterogeneity of the population analyzed in each trial,
which differs in relation to age, lifestyle, comorbidity, treatments,
and ethnicity as well as the different degrees of iodine intake (18).
Indeed, in people with sufficient iodine intake, a higher prevalence
of both thyroid autoimmunity and hypo is generally observed as
compared to individuals living in iodine insufficient areas (33).
Accordingly, in the Wickham survey, the prevalence of sHT was
7.5% but rose from 7.5 to 17.4% while considering older women
(>75 years) with positive serum anti-thyroid antibody titers (28).
In the Colorado STUDY, 21% of women and 16% of men older
than 74 years suffered from mild thyroid deficiency (10). Interest-
ingly, the prevalence of sHT decreased by 2% for patients older
than 75 years and by 5% for those older than 90 years while using
an age-specific reference range (7, 12, 24). Another crucial aspect
to keep in mind is the rate of progression from mild to overt
hypothyroidism. Indeed, a significant number of subjects experi-
enced no progression and even normalization of serum TSH value
(34, 35).
In conclusion, the prevalence and the clinical impact of sHT
as reported by scientific literature always should be interpreted in
relation to the demographic, ethnic, and lifestyle characteristics
of the studied population. Moreover, the actual presence of sHT
should be confirmed by at least two measurements, with sufficient
interval, of serum TSH level.
THYROID HORMONES AND THE CARDIOVASCULAR SYSTEM
Subclinical hypothyroidism might be interpreted as an interme-
diate alteration between full-blown thyroid failure and euthy-
roidism. Thus, changes of CV system induced by sHT qualitatively
resemble those observed in overt hypothyroidism even if less
evident. Since TH influence each structure of the heart and its
conducting system, the relationship between thyroid dysfunction
and CV disease goes well beyond the risk of atherosclerosis and
atrial fibrillation (1, 36, 37). TH, mainly FT3, regulate myosin
heavy chain genes, which encode for the two contractile pro-
tein isoforms of the thick filament of the cardiomyocyte (38–41).
TH also induce expression of the sarcoplasmatic reticulum Ca2-
ATPase and reduce the expression of its inhibitor, phospholamban
(42). Accordingly, reduced heart output along with prolonged
isovolumic relaxation phase, leading to an early cardiac impair-
ment, has been described in hypothyroidism (43). Many studies
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documented similar alteration also in sHT patients (44–46). Sys-
tolic function impairment with increased pre-ejection/ejection
time ratio and mean aortic acceleration has been shown in sHT
patients (47–49). Decreased cardiac preload along with increased
after load, leading to a reduction of cardiac output, was con-
firmed by magnetic resonance study (50). Interestingly, similar
functional modifications are described during the aging process,
thus it is not surprising that sHT may worsen the age-related car-
diac process resulting in increased risk of HF progression and
events (51). Moreover, cardiac alterations associated with sHT are
generally reversed after restoration of euthyroidism by l-thyroxine
replacement (44, 47, 52).
Thyroid hormones also affect endothelium and smooth mus-
cle cell function, leading to reduced vascular tone (38). Sev-
eral mechanisms for T3-mediated vascular relaxation have been
reported (37, 38, 53, 54). As stated by Klein et al., T3 induces
in vitro relaxation of smooth muscle cells independently of NO
production, suggesting a direct effect of the hormone (38). Dar-
dano et al. showed that, in patients monitored for differentiated
thyroid cancer, the administration of recombinant human TSH
acutely impaired endothelium-dependent vasodilation, possibly
through the induction of low-grade inflammation and reduced
NO availability by oxidative stress, suggesting a possible role of
TSH per se in endothelial dysfunction (55). Moreover, sympa-
thetic and adrenal activation may contribute to the development
of arterial hypertension in hypothyroid individuals (56–58).
Overall, these findings suggest that sHT affects CV system by
complex mechanisms involving both myocardium and vascula-
ture. These effects are partially similar to those typically observed
in the aging process, making difficult to distinguish CV changes
of aging from those directly belonging to sHT. Both the degree of
serum TSH increase and its long-lasting effect have been claimed
to concur to the development of sHT effects at tissue level (59, 60).
Thus, exposition to minute thyroid hormone deficiency may, over
time, be associated with increased risk of CV diseases. However,
the actual burden of mild thyroid failure on the CV system of older
people remains to be established and still is widely debated (1, 38).
HEART FAILURE AND sHT IN THE ELDERLY
Heart failure, defined as an impaired ability of the ventricle to fill
with or eject blood, represents a common clinical condition with
increasing prevalence in the last decades of life (61, 62). More than
20 million people suffer from HF worldwide (63), and its preva-
lence and incidence are increasing mostly because of increasing
lifespan, and also because of increased prevalence of risk fac-
tors (diabetes mellitus, systemic hypertension, dyslipidemia) and
improved survival rates from other types of CV diseases (64). In
2011, HF was the most common reason for hospitalization for
individuals older than 85 years and the second most common for
those aged 65–85 years (65). Since sHT has been described to be
associated with conditions that may concur to the development of
HF (66–68), several prospective studies have been designed to eval-
uate the possible relationship between mild thyroid dysfunction
and HF with discordant results (66, 69–71). As above described, the
effect of TH deficiency on CV system is partially similar to that typ-
ically observed in the aging process (interstitial fibrosis, myocyte
loss, cardiac remodeling). However, few studies directly examined
the relationship between sHT and HF in elderly people (70–75).
Rodondi et al. studied 3044 adults older than 65 years and initially
free of HF over a mean 12-year follow-up (70). An increased risk
of HF was observed in subjects with TSH above 10.0 mIU/l with
HF incidence of 41.7/1000 vs 22.9/1000 person per year in euthy-
roid individuals (p= 0.01). Interestingly, no increased incidence
was observed in subjects with serum TSH level between 4.5 and
9.9 mIU/l, even after stratification by TSH concentration below
or above 6.9 mIU/l. Accordingly, among 5316 older adults (aged
70–82 years) an increased HF risk (HR 3.0, 95%CI: 1.12–8.11)
was observed only in individuals with serum TSH value above
10.0 mIU/l after 3.2 years of follow-up (51). Nonetheless, in a pre-
vious study on community-dwelling older people (2730 subjects
aged 70–79 years with a follow-up of 4 years) those with serum
TSH level between 7.0 and 10.0 mIU/l showed an increased risk
of HF (HR 2.58, 95% CI: 1.19–5.60) but not of other CV events
or mortality (72). Moreover, mild elevated TSH (<10.0 mIU/l)
represented a negative prognostic factor for increased cardiac and
all-cause mortality in hospitalized patients (3121 patients, mean
age 61.1 years) with acute HF events (73).
At odds with these results, in a study performed in 5888
community-dwelling individuals aged over 65 years, those with
sHT did not show an increased HF risk, even for TSH values
above 10.0 mIU/l. Moreover, in a time-varying model, in which
thyroid status was updated with subsequent TSH measurements,
there was no association between sHT and incident HF (74). Sim-
ilarly, patients older than 60 years with serum TSH value above
5.0 but less than 8.0 mIU/l did not show an increased risk of hos-
pitalization for HF (HR 1.23, 95% CI: 0.96–1.56) (75). The lack
of an association between mild thyroid failure and HF was also
reported by a very recent prospective study in subjects aged over
65 years (76). Possible explanations of these conflicting results may
be the different ethnic compositions, mean age, and comorbidity
of the study populations as well as the different degrees of serum
TSH elevation and length of follow-up. Moreover, since in many
individuals TSH normalizes over time (15–65% over follow-up
periods going from 1 to 6 years), a possible fluctuation of thy-
roid dysfunction over time might have contributed to the negative
findings of some studies, especially in case of single serum TSH
determination (35).
In conclusion, most studies showed an increased risk of HF
progression and events in sHT patients, although with different
strengths of association and, generally, for serum TSH value above
10.0 mIU/l (51, 70–72). Accordingly, a recent meta-analysis of
6 large, prospective studies on community-dwelling older indi-
viduals confirmed that sHT patients have an age-independent
increased rate of HF, although only for serum TSH value above
10.0 mIU/l (77). Finally, although small case-control studies,
mainly performed in young adults, have shown that restoration
of euthyroidism by LT4 therapy is able to improve indexes of car-
diac function (47, 52); no large, randomized, controlled trials have
been performed to date to evaluate the efficacy of LT4 replacement
in preventing HF progression and events.
CORONARY HEART DISEASE AND sHT IN THE ELDERLY
Conflicting data still exist regarding the association between sHT
and CHD; some studies reporting increased risk (4, 5, 78), some
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decreased (76), and some the lack of any association (72, 79–
83). Since inconsistent data were especially obtained in the elderly
(Table 1) the risk of CHD in sHT patients has been suggested to be
confined to young adults (<65 years). Nonetheless, most reports
did not accurately explore the possible age-related differences in
CHD risk, even in case the elderly represented a large share of the
enrolled population.
In this setting, a recent large meta-analysis showed no evidence
of a gradient of CHD risk while stratifying data by age (93). More-
over, in the Rotterdam study [1149 postmenopausal women aged
69.0± 7.5 years (mean± SD)] sHT was associated with a greater
age-adjusted prevalence of aortic atherosclerosis [odds ratio, 1.7
(95% CI 1.1–2.6)] and myocardial infarction [MI, odds ratio, 2.3
(95% CI 1.3–4.0)]. Additional adjustment for body mass index,
lipoprotein profile, systemic blood pressure, and smoking status, as
well as the exclusion of women taking beta-blockers, did not affect
these estimates (84). Similarly, Lindeman et al. documented a sig-
nificantly higher prevalence of CHD in patients older than 65 years
with elevated serum TSH (>10.0 mIU/l) as compared to those with
normal TSH value (85). Conversely, most naturalistic studies did
not find any association between sHT and increased CHD events or
mortality among older people (86–90,92), even if one documented
increased all-cause mortality (81). The Women’s Health Initiative
survey (90) examined the association between sHT and MI by
measuring serum TSH and FT4 in 736 women with incident MI as
compared to 2974 randomly selected individuals. After 5–10 years
of follow-up, the Hazard ratio for MI was 0.99 (95% CI: 0.67–1.46)
for women with serum TSH between 4.69 and 6.99 mIU/l, and
1.19 (95% CI: 0.72–1.96) for those with TSH≥ 7.0 mIU/l (90). It
should be underlined, however, that no information about the use
of thyroid medication was available beyond 3 years of follow-up
and thyroid function testing was performed only at the begin-
ning. However, Hyland et al., in a prospective study on 4863 older
people (> 65 years), in which thyroid status was updated with sub-
sequent TSH measurements, did not find any association between
persistent or transient sHT and incident CHD (HR 1.37, 95% CI:
1.00–1.87 and HR 1.00, 95% CI: 0.68–1.49, respectively) or CV
death (HR 0.97, 95% CI: 0.64–1.48 and HR 0.99, 95% CI: 0.70–
1.39, respectively). Additional analysis stratified by the degree of
serum TSH elevation (4.5–6.9; 7.0–9.9, and 10.0–19.9 mIU/l) con-
firmed the negative findings (74). Another prospective study on
1587 community-dwelling older men (> 65 years) did not find
any association between sHT and CV events or total mortality
notwithstanding the rate of TSH elevation, but serum TSH higher
than 10.0 mIU/l was detected only in eight men (89). Moreover,
a cross-sectional study with subgroup analyses by age confirmed
that increased CHD risk was present only in younger sHT partic-
ipants (<50 years old) (94). Accordingly, a meta-analysis of five
studies demonstrated that sHT is associated with increased CHD
prevalence and events only in young adults (aged< 65 years), in
whom an increased incidence of CHD was observed also for serum
TSH value lower than 10.0 mIU/l (95). Interestingly, a very large,
recent meta-analysis clearly demonstrated that, in age- and sex-
adjusted analyses, the risk of CHD events and mortality increases
with rising serum TSH level, reaching the statistical significance
only in patients with TSH values above 10 mIU/l regardless of
patients’ age (93).
In summary, the negative effect of sHT on CHD events
and mortality appears well established in subjects younger than
65 years but less evident in older people. The inconsistency in
results among studies in elderly patients may be due either to the
duration of tissue exposure to sHT or of follow-up, as well as
to the presence or not of comorbidity (pre-existing CV or other
chronic diseases). The most representative meta-analyses on the
association between sHT and CHD risk are reported in Table 2.
CEREBROVASCULAR DISEASE AND sHT
Subclinical hypothyroidism is postulated to increase stroke risk via
atherogenic changes associated with abnormal thyroid function.
However, the direct relationship of sHT with subsequent stroke
is poorly studied. Some naturalistic studies suggest that sHT is
not associated to cerebral ischemic events, and a better outcome
of patients affected by sHT with respect to those without thyroid
failure has been reported (72, 98, 99). In detail, a large naturalistic
study (2730 individuals aged 70 to 79 years) with 4-year follow-up
data showed that sHT was not associated with a higher preva-
lence of either CV events (including stroke) or total mortality
(80). Schultz et al. (99) prospectively evaluated 609 community-
dwelling individuals older than 50 years showing no increase of
incident stroke among sHT subjects also after adjusting data by
the degree of serum TSH elevation. These data are partially at
odds with those from the Women’s Health Initiative Observational
Study (98), in which the potential relationship between incident
ischemic stroke and severity of sHT was prospectively assessed in
postmenopausal women (639 ischemic stroke cases and 2927 ran-
domly selected sub-cohort members with 7 years of follow-up).
The adjusted hazard ratio from weighted Cox models resulted
modestly elevated (1.22, 95% CI, 0.73, 2.05) only for sHT women
with serum TSH value higher than 7.00 mIU/l. However, giving the
wide range of 95% CI, the data appeared not sufficiently consistent
to suggest a clear-cut association between sHT and ischemic stroke,
in otherwise healthy postmenopausal women. In this setting, it is
noteworthy that among 756 patients with acute ischemic stroke
those with sHT at admission were more likely to show favorable
functional outcomes (100).
In conclusion, available data suggest that sHT has no impact
on cerebral ischemic events or the effect is too small to be detected
in naturalistic studies. Preconditioning before stroke along with
reduced response to stress could represent the possible protective
mechanism exerted by sHT in the outcome of patients with stroke.
More studies are clearly warranted to better address this topic with
dedicated epidemiological assessment.
sHT AND CV MORTALITY
Although an association between sHT and a greater all-cause and
CV mortality (73, 87, 101, 102) has been generally documented in
individuals with underlying high CV risk (patients at high risk
for or who had recent cardiac events), it has not always been
observed in general population (23, 72, 79, 80, 88, 89). Indeed,
a large population-based, longitudinal study of CHD and stroke
in subjects older than 65 years failed to support the hypothesis
of an association between unrecognized sHT and increased CV
events or mortality (80). Although no difference in the associa-
tion between sHT and mortality among patients with and without
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Table 1 | Most representative prospective or cross-sectional studies on subclinical hypothyroidism and cardiovascular risk.
Reference Study design Study
population
Participants
(sHT)
Age (years) TSH (mIU/l) Follow-up
(years)
Analyzed
endpoint
Outcome
Hak et al. (84) Cross-sectional Postmenopausal
women
1149 (124) 96.0±7.9 >4.00 NA CVE OR 2.3 (CI 1.3–4.2)
Parle et al. (83) Prospective Community
dwelling
1120 (94) >60 >5.00 10 CVM HR 0.9 (CI 0.6–1.3)
Lindeman et al. (85) Cross-sectional Community
dwelling
755 (112) 74.1±8.2 NA NA CVE p=0.0007 (TSH>10.0)
Imaizumi et al. (78) Prospective Community
dwelling
2650 (257) 62.7±11.1 7.16±4.82 12.2 ACM,
CVE
HR 1.9 (CI 1.1–3.2),
in men only
OR 2.5 (CI 1.1–5.5)
Gussekloo et al. (23) Prospective Community
dwelling
502 (30) >85 >4.8 4 ACM HR 0.76 (0.62–0.92)
van den Beld et al. (22) Prospective Community
dwelling
359 (6) 77.8 (73–94) >4.3 4 Survival NS
Cappola et al. (80) Prospective Community
dwelling
3135 (496) 72.7±5.6 6.67±2.54 13 CVM,
CVE
HR 1.14 (CI 0.91–1.43),
HR 1.04(CI 0.87–1.23)
Iervasi et al. (73) Prospective Hospitalized
cardiac patients
2113 (208) 61.1 (60.7–61.5) 6.7 (6.01–7.44) 2.7 ACM,
CVM
HR 2.0 (CI 1.33–3.04),
HR 2.4 (CI 1.36–4.21)
Bauer et al.(86) Prospective Community
dwelling
438 (37) 71.5±5.0 >5.50 11.9 Survival HR 1.23 (CI 0.55–2.74)
Razvi et al.(5) Prospective Community
dwelling
2376 (97) 49.9±17.9 6.00–15.00 20 CVE,
CVM
HR 1.76 (CI 1.15–2.71),
HR 1.79 (1.02–3.56) 1
McQuade et al. (87) Retrospective Community
dwelling
6240 (1396) EU: 54.6±12.7, Mild
sHT: 57.1±13.3,
Moderate sHT:
58.9±13.6
Mild sHT: 3.1–6.0,
Moderate sHT:
6.1–10.0
8 ACM p=0.026 in moderate
sHT people
aged>65 years
de Jongh et al. (88) Prospective Community
dwelling
1219 (34) >65 6.89 (5.65–9.59) 10.7 ACM,
CVM
HR 0.9 (CI 0.58–1.42),
HR 0.5 (CI 0.20–1.49)
Waring et al. (89) Prospective Community
dwelling
1503 (116) 74 4.79–10.00 8.3 ACM,
CVM
HR 1.01 (CI 0.7–1.4),
HR 1.28 (CI 0.8–2.1)
(Continued)
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Table 1 | Continued
Reference Study design Study
population
Participants
(sHT)
Age (years) TSH (mIU/l) Follow-up
(years)
Analyzed
endpoint
Outcome
Hyland et al. (74) Prospective Community
dwelling
4863 (697) 73.4±5.7 6.7±2.6 10 CVE,
CVM
HR 1.37 (CI 1.0–1.87),
HR 0.89 (CI 0.64–1.48)
LeGrys et al. (90)a Prospective Postmenopausal
women
3663 (282) 65–79 >4.69 >5 CVE:
TSH 4.69–6.99,
TSH>7.00,
TSH 4.69–6.99,
TSH>7.00
Age 65–70:
HR 0.99 (CI 0.42–2.35),
HR 1.11 (CI 0.51–2.39);
Age 71–79:
HR 0.53 (CI 0.13–2.26),
HR 1.27 (CI 0.44–3.69)
Rhee et al. (91) Prospective Community
dwelling
2570 (691) sHT: 59.2±19.2 6.3 (5.3–8.72) 14.3 ACM Pre-existing HF:
HR 1.77 (CI 1.19–2.64),
No pre-existing HF:
HR 0.97 (CI 0.84–1.12)
Ceresini et al. (92) Prospective Community
dwelling
951 (29) >65 >4.68 6 CVM HR 0.50 (CI 0.10–2.55)
Yeap et al. (82) Prospective Community
dwelling men
3885 (416) 70–89 >4.00 6.4±1.5 ACM HR 1.06 (CI 0.86–1.32)
Frey et al. (69) Prospective Hospitalized
cardiac patients
1032 (34) sHT 62±12, EU 67±13 5.29 (4.02–9.38) 3.08 (1.5–3.58) ACM HR 0.96 (CI 0.52–1.77)
Perez et al. (75)b Prospective Community
dwelling
4987 (237) >60 6.40 (5.60–8.00) 2.73 CVM,
ACM
HR 1.46 (CI 1.16–1.84),
HR 1.36 (CI 1.03–1.76)
aFirst-time incident myocardial infarction.
bTSH value lower than 8.00 mIU/l but no distinction between sHT and overt hypothyroidism. Age and TSH value are reported as mean±SD or median (confidence interval or range).
sHT, subclinical hypothyroidism; EU, euthyroidism; HR, hazard ratio; OR, odds ratio; ACM, all-cause mortality; CVM, cardiovascular mortality; CVE, cardiovascular events; NS, not significant; NA, not available.
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Table 2 | Most representative meta-analyses on the relationship between subclinical hypothyroidism and coronary heart disease.
Reference Number
of studies
Study population
(subjects with sHT)
Age Endpoint Outcome
Whole cohort Subjects older than 65years
Singh et al.
(97)
6 11,495 (935) 58–75 CHD events RR 1.18 (CI 1.02–1.37) NA
CVM RR 1.11 (CI 0.99–1.25)
Haentjens
et al. (102)
9 13,329 (290) 50–85 CVM HR 1.22 (95% CI 0.96–1.57) NA
Ochs et al. (66) 10 14,449 (1491) 46–85 CHD events HR 1.20 (95% CI 0.97–1.49) <80 and HR 1.06 (95% CI 0.91–1.24)
>80 and HR 0.47 (95% CI 0.11–1.90)
CVM HR 1.18 (95% CI 0.98–1.42) <80 and HR 1.12 (95% CI 0.99–1.28)
>80 and HR 0.55 (95% CI 0.24–1.25)
Razvi et al. (95) 15 29,022 (2531) 42–85 CHD events HR 1.27 (95% CI 0.95–1.22) HR 1.02 (95% CI 0.85–1.22)
CVM HR 1.09 (95% CI 0.84–1.41) HR 0.85 (95% CI 0.56–1.29)
Rodondi
et al. (93)
11 55,287 (3450) 46–85 CHD events HR 1.18 (95% CI 0.99–1.42) <80 and HR 1.20 (95% CI 0.95–1.51)
>80 and HR 1.30 (95% CI 0.93–1.82)
CVM HR 1.09 (95% CI 0.96–1.24) <80 and HR 1.32 (95% CI 1.08–1.62)
>80 and HR 1.01 (95% CI 0.62–1.63)
sHT, subclinical hypothyroidism; CHD, coronary heart disease; CVM, cardiovascular mortality; HR, hazard ratio; NA, not available.
underlying CV disease was detected by Rodondi et al. (93), in
a more recent meta-analysis, pre-existing congestive HF signif-
icantly worsened the relationship between sHT and HF events
(77). It is plausible that subpopulations with congestive HF may
be predisposed to cardiac morbidity and mortality associated
with sHT. In agreement with this hypothesis, only sHT patients
(aged 59.2± 19.2 years, mean± SD) with congestive HF showed a
greater risk of all-cause mortality compared to euthyroid individ-
uals (HR 1.77, 95% CI: 1.19–2.64) (91). Moreover, Iervasi et al.,
among 3308 patients attending a Cardiology Clinic, documented
an increased risk of cardiac death in those with sHT (HR 2.40,
95% CI: 1.36–4.21), after 32 months of follow-up (73). There
are few clinical studies evaluating the effects of hormone replace-
ment in sHT subjects and none aimed at determining the impact
of LT4 treatment on total mortality, especially in older people.
Previous research in this area has shown contradictory results,
with some randomized, controlled trials showing an improvement
of both dyslipidemia and surrogate endpoints of atherosclerosis
(36, 103, 104) not documented by previous, uncontrolled studies
(105–108).
In conclusion, the relationship between mild thyroid failure and
increased risk of cardiac and all-cause mortality is far from being
established and widely accepted, especially in the elderly. A nega-
tive effect of sHT on HF progression and events nonetheless has
been documented in older individuals with underlying high CV
risk. Large, randomized intervention studies are currently ongoing
in older people with sHT and will share new insight in this still
unresolved issue (109).
sHT AND QoL IN THE ELDERLY
Quality of life has been defined by the World Health Organiza-
tion as “an individual’s perception of their position in life in the
context of the culture and value system in which they live, and
in relation to their goals, expectations, standards and concerns”
(110). Thus, patients are the best judges of their own perceived
QoL. Measuring health status is imperative, especially in case of
chronic diseases in which long-term survival is not at risk and
the goal of treatment is to maintain patients symptom-free and
living in the community. Symptoms and QoL in hypothyroidism
were assessed by a large number of instruments, which can be
broadly divided into two categories: generic and disease specific
(111); most used generic tools, validated in thyroid failure and used
in various thyroid disorders, are the Short Form36 (SF-36), the
Nottingham Health Profile (NHP), and the General Health Ques-
tionnaire (GHQ) (111–115). Various validated thyroid-specific
questionnaires were also developed: the Chronic Thyroid Ques-
tionnaire (CTQ), the Underactive-Thyroid-Dependent Quality
of Life Questionnaire (ThyDQoL). and the Underactive Thyroid
Treatment Satisfaction Questionnaire (ThyTSQ) (116–119). It is
well known that overt hypothyroidism slows metabolism, with
classical symptoms as tiredness, fatigue, and weight gain, and
induces neuromuscular symptoms and cognitive problems (1).
Moreover, overt hypothyroidism is associated with high psychi-
atric morbidity, in particular depression and paranoid disorders
(120, 121). Thus, it is not surprising that overt thyroid failure is
associated with impaired QoL (112, 116, 117, 122). It is generally
recognized that sHT encompasses symptoms comparable to those
observed in the overt form of the disease, although to a lesser
extent (10). Mild thyroid failure has been associated with mood
and cognitive alterations as well as neuromuscular abnormalities
(48, 120, 121, 123, 124). To date, however, the literature regarding
the effects of sHT on QoL is sparse and inconclusive (114, 115,
117, 125, 126). The largest naturalistic study suggested that sHT
does not significantly affect health-related QoL (114, 115), while
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other studies carried out in sHT patients referring to endocrine
out-patient clinics documented a significant decrease of QoL (125,
127). Scanty data are also available on the effect of LT4 replace-
ment therapy on QoL (107, 128–130). Some studies did not find
a significant modification of health-related QoL (107, 128), while
others documented an improvement by restoring euthyroidism
(129–131). As in adult population, some observational studies sug-
gested an association between sHT and mood disorders in older
people that could worsen QoL (120, 132). In detail, in 323 sub-
jects older than 60 years, Chueire et al. showed that sHT increases
the risk for depression (OR 4.9, 95% CI 2.8–8.6) (120). Moreover,
of 163 sHT older patients (>65 years) attending a general medical
clinic, 75% had a lifetime diagnosis of major depression compared
with 18% of euthyroid subjects (132). Others studies, however, did
not confirm this association (23, 88, 126).
Although older individuals could be more susceptible to the
effects of a disease for their possible frailty, few studies were
specifically designed to assess the effect of sHT on QoL in older
population (126, 133). Functional capacity as assessed by ADL
and IADL plays a fundamental role in determining QoL of older
people. The majority of the studies, however, reported no associ-
ation between sHT and functional impairment (23, 96, 126, 133,
134). Simonsick et al. documented that individuals aged between
70 and 79 years with mild TSH elevation (4.5–7 mIU/L) had faster
mean and usual gait speed and better cardiorespiratory fitness than
euthyroid controls (96). In addition, a prospective, observational,
population-based study carried out on 599 participants followed
up from age 85 to 89 years showed no association between serum
TSH and FT4 levels and disability in daily life, depressive symp-
toms, and cognitive impairment at baseline or during follow-up.
Increasing serum TSH levels were associated with a lower mor-
tality rate that remained after adjustments for baseline disability
and health status (23). In a very recent population-based prospec-
tive study, the Octabaix study, 307 (184 females) inhabitants older
than 85 years were submitted to complete multifunctional assess-
ment, including Barthel and Lowton indexes, mini mental state
examination (MMSE), mini nutritional assessment (MNA), gait
rating scale, and quality of life test (EQ-VAS). Compared to
euthyroid subjects (n= 280), those with sHT (n= 20) did not
show any difference either in QoL, or in functional and cognitive
status (133).
Overall, these data support the hypothesis that in the oldest
old population, individuals with abnormally high levels of TSH
do not experience adverse effects and may have a prolonged life
span. The studies focused on a specific class of patients (older
than 85 years), and the results should be carefully interpreted, also
considering the weakness of observational studies. Nonetheless,
these data together with the results obtained by Rozing et al. (20)
that demonstrated a possible genetic predisposition of nonage-
narians to a decrease function of hypothalamus-pituitary-thyroid
axis suggest that the oldest old may represent a different popula-
tion with respect to moderate old people or young adults. In this
setting, however, the lack of association between mild hypothy-
roidism and poor QoL as assessed by SF-36 was observed also
in individuals older than 65 years, without known thyroid dis-
ease who had participated in the Korean Longitudinal Study on
Health and Aging (126). Thus, the observation of a progressive
shift of the normal serum TSH range toward higher values
from healthy young individuals up to centenarians (7) may indi-
cate a certain degree of down-regulation of the hypothalamus–
pituitary–thyroid-peripheral axis and a possible adaptive response
to age-related metabolic changes.
CONCLUSION
Consistent results among large prospective cohort studies suggest a
relationship between sHT and HF progression and events in older
people, while an impact of sHT in terms of CHD events and mor-
tality is recognized only in young adults (<65 years). Moreover,
in the oldest old population (>85 years) one study suggested that
high levels of TSH not only do not exert adverse effects but also
may favor a prolonged lifespan. Limited reports are available on
QoL of elderly people, and the lack of an association between sHT
and poor QoL is generally reported. Thus, moderately old patients
(65–75 years) could be considered clinically similar to the adult
population, albeit with a higher optimal TSH target value (around
2–3 mIU/l), whereas oldest old subjects (>80–85 years) should be
carefully followed with a wait-and-see strategy, generally avoiding
hormonal treatment (18, 135).
Large, randomized, prospective studies are nonetheless war-
ranted to assess whether sHT actually affects CV disease progres-
sion and events as well as health-related QoL in older people,
analyzing results according to the age groups of participants.
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